In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


INTERVIEW: Nanobiotix’s nanoparticles bring big benefits to radiotherapy

This article was originally published in Clinica

Executive Summary

Bells and whistles may sound nice but simplicity always wins hands down. Indeed, keeping it simple was how cancer nanotech firm Nanobiotix captured public investors’ interest to successfully raise €14.2 million ($18.5 million) when it floated on the EuroNext stock exchange last year. Not a bad outcome for an early clinical stage company amidst a sluggish medtech IPO market.


Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts